Management of afatinib-induced stomatitis

Kato, Saeko; Saito, Anna; Matsuda, Naomi; Suzuki, Hisako; Ujiie, Midori; Sato, Shinya; Miyazaki, Kunihiko; Kodama, Takahide; Satoh, Hiroaki

doi:10.3892/mco.2017.1184

Cited by 10 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chamomile ( Matricaria recutita ) is a medicinal plant widely used in traditional medicine for its anti-oxidant, anti-microbial, and anti-inflammatory actions (Gomes et al, 2018 ), which seems to be a promising alternative for the treatment of 5-fluorouracil-induced oral mucositis and recurrent aphthous stomatitis (Seyyedi et al, 2014 ; Gomes et al, 2018 ). Aznol mouthwash combined with chamomile extract and Hangeshashinto, alleviates stomatitis in a small cohort of lung cancer patients treated with afatinib (Kato et al, 2017 ). Aloe vera , an herbal medicine in tropical area, has been used to treat skin disorders with anti-bacterial and wound-healing effects.…”

Section: Prevention Of Oral Mucositis Partly By Reducing Oxidative Stmentioning

confidence: 99%

Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects

et al. 2018

View full text Add to dashboard Cite

Cancer is the second leading cause of death in the world. Chemotherapy and radiotherapy are the common cancer treatments. However, the development of adverse effects resulting from chemotherapy and radiotherapy hinders the clinical use, and negatively reduces the quality of life in cancer patients. Natural products including crude extracts, bioactive components-enriched fractions and pure compounds prepared from herbs as well as herbal formulas have been proved to prevent and treat cancer. Of significant interest, some natural products can reduce chemotherapy and radiotherapy-induced oral mucositis, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, hematopoietic system injury, cardiotoxicity, and neurotoxicity. This review focuses in detail on the effectiveness of these natural products, and describes the possible mechanisms of the actions in reducing chemotherapy and radiotherapy-induced side effects. Recent advances in the efficacy of natural dietary supplements to counteract these side effects are highlighted. In addition, we draw particular attention to gut microbiotan in the context of prebiotic potential of natural products for the protection against cancer therapy-induced toxicities. We conclude that some natural products are potential therapeutic perspective for the prevention and treatment of chemotherapy and radiotherapy-induced side effects. Further studies are required to validate the efficacy of natural products in cancer patients, and elucidate potential underlying mechanisms.

show abstract

Section: Prevention Of Oral Mucositis Partly By Reducing Oxidative Stmentioning

confidence: 99%

Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A total of 7 articles were read in full, and of these, 6 met the inclusion criteria after all stages of search selection and refinement, according to a flowchart based on the PRISMA model (Figure 1) (Moher et al, 2009). In the last refinement step, the study of Kato et al (2017) was excluded, because of the management of stomatitis mediated by tyrosine kinase inhibitors. A secondary active search was performed and 24 studies were included to complement the theoretical foundation.…”

Section: Resultsmentioning

confidence: 99%

Action of Matricaria recutita (chamomile) in the management of radiochemotherapy oral mucositis: A systematic review

Dantas

Fortuna

Sanches

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

The objective of this study was to evaluate the effect of topical chamomile in the prevention and/or treatment of oral mucositis (OM) in cancer patients. It was a systematic review, which sought articles of the randomized clinical trial according to the PRISMA parameters, registered in the PROSPERO. The databases used were PubMed, Cochrane Library, and Bireme. Descriptors were selected from DeCs/MeSH and the PICO strategy was applied. The search found 148 publications. After all the steps, six articles were selected. The total sample included 492 patients and all studies used the same OM measurement scale. The results showed that the application of topical chamomile was effective in the prevention and/or treatment of OM in four of the six studies, with a dose ranging from 1% to 2.5% and duration that ranged from single to 4 times a day. Some limitations were observed: the minimum age of the patients was not informed, and there was no specification of the sites involved or the chemotherapies used. The application of topical chamomile in the preventive/therapeutic of chemo‐induced OM seems to be recommended. In addition, scientific production should be encouraged, as it aims to determine useful protocols for this phytotherapy for the oncology population.

show abstract

“…EGFR-TKIs are generally maintained for grades 1 and 2. They are temporarily stopped for grade 3 until stomatitis or mucositis improves to grade 2, after which it is resumed at 50% of the initial dose, then increased if symptoms do not worsen [77].…”

Section: Tolerability Profile Of Tkis: Safety and Side Effectsmentioning

confidence: 99%

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management

2019

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The discovery of several oncogenic driver mutations in patients with NSCLC has allowed the development of personalized treatments based on these specific molecular alterations, in particular in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene. Gefitinib, erlotinib, afatinib, and osimertinib are TK inhibitors (TKIs) that specifically target EGFR and are currently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first line treatment for sensitive EGFR-mutant patients. However, these four drugs are associated with severe adverse events (AEs) that can significantly impact patient health-related quality of life and patient monitoring. EGFR-TKIs are commonly used together with other types of medication that can substantially interact. Here, we review approaches used for the management of TKI-AEs in patients with advanced NSCLC to promote the benefits of treatments and minimize the risk of TKI treatment discontinuation. We also consider potential TKI–drug interactions and discuss the usefulness of plasma concentration monitoring TKIs based on chromatographic and mass spectrometry approaches to guide clinical decision-making. Adjusting the most appropriate therapeutic strategies and drug doses may improve the performance therapy and prognosis of patients with advanced EGFR-mutated NSCLC.

show abstract

Management of afatinib-induced stomatitis

Cited by 10 publications

References 20 publications

Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects

Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects

Action of Matricaria recutita (chamomile) in the management of radiochemotherapy oral mucositis: A systematic review

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management

Contact Info

Product

Resources

About